Switzerland-based Siegfried has purchased a 95% stake in DiNAMIQS, a biotechnology firm that focuses on the development and production of viral vectors for cell and gene therapies.
Siegfried will leverage DiNAMIQS’ capabilities to commercial scale by constructing a facility that complies with good manufacturing practice standards.
The facility will be situated with DiNAMIQS’ existing operations at Bio-Technopark in Zurich-Schlieren, Switzerland, and is anticipated to become operational in 2025.
DiNAMIQS’ parent company, DiNAQOR, will own the remaining 5% stake in the firm.
The deal includes an option for Siegfried to purchase this remaining 5% five years after the acquisition.
The move represents Siegfried’s strategy to expand its presence in biologics, and provides important growth opportunities in the mid to long term.
DiNAMIQS will initially continue to run under its own name and as a mostly independent venture within Siegfried.
DiNAMIQS and its clients will take advantage of the integration of its drug substances production activities into Siegfried’s capabilities, as well as the capacities for the aseptic filling and completion of complex biological entities at its facilities in Hameln, Germany, and Irvine in the US.
Siegfried CEO Dr Wolfgang Wienand stated: “With this acquisition, we are entering the rapidly growing space of cell and gene therapies where viral vector-based technologies support the majority of clinical candidates in a rich development pipeline.
“In our view, this approach of an initial small-scale acquisition of a highly capable technology platform followed by flexible bolt-on investments into capabilities and capacities in line with actual market needs, provides significant value upside at reasonable entry costs.
“This is perfectly in line with our EVOLVE strategy and our track record of disciplined execution of value-adding mergers and acquisitions – and a further step towards our vision of creating a leading contract development and managing organisation in our space.”
Source: pharmaceutical-technology.com
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
